Dr. Levy, along with Drs. Ambinder and Muggia, will be outstanding co-chairs in steering this symposium that focuses on the advances that continue to rapidly occur at a staggering and unprecedented pace in virtually all aspects of cancer care...
Past News ReleasesRSS
PLAINSBORO, N.J. (PRWEB) March 30, 2016
Physicians’ Education Resource®, LLC (PER®), the leading source for oncology and hematology continuing medical education (CME), today announced that Dr. Benjamin Levy will be the third co-chair at the 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® from November 9-11 at the New York Marriott Marquis in New York City.
Presently the director of thoracic medical oncology at Mount Sinai Health Systems and assistant professor of medicine at the Icahn School of Medicine, Dr. Levy will work with the other co-chairs to guide the overall symposium. His co-chairs include Dr. Edward Ambinder, clinical professor of medicine, hematology and medical oncology, and clinical professor of oncological sciences, at Mount Sinai Hospital, and Dr. Franco Muggia, professor, department of medicine, at NYU Langone Medical Center.
Dr. Levy has a nationally known reputation as an expert in the field of lung cancer and has extensive experience leading clinical trials evaluating next-generation systemic, targeted and immune-based therapies for treating cancer. Additionally, he has received an extensive amount of oncology leadership appointments, awards/honors, speaking engagements and publishing opportunities. Dr. Levy also has served as faculty and chair on a wide variety of CME activities and is well-versed on innovative treatment formats that drive outcomes.
The annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow is recognized as one of the premier multi-tumor oncology/hematology meetings worldwide. Now in its fifth decade, this unique oncology educational event attracts an audience of more than 2,000 oncologists, hematologists, radiation oncologists, immunologists, oncology nurses, nurse practitioners, physician assistants and case managers to discuss cutting-edge advances in cancer therapy across solid and hematologic malignancies, and to share ideas with their peers.
“Dr. Levy, along with Drs. Ambinder and Muggia, will be outstanding co-chairs in steering this symposium that focuses on the advances that continue to rapidly occur at a staggering and unprecedented pace in virtually all aspects of cancer care, including diagnosis, treatment and personalized management,” said PER President Phil Talamo. “In addition to our three co-chairs, our outstanding faculty of leading clinical innovators in virtually every tumor subspecialty will provide expert insights on new developments in cancer therapeutics. They will also provide oncology professionals with the opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials, and emerging developments that define current progress aimed at the goal of control and cure of cancer.”
Individuals interested in the 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow can register here.
About Physicians’ Education Resource
As a leader in continuing medical education (CME) for nearly 20 years, Physicians’ Education Resource (PER) educates more oncologists and hematologists through live annual CME-certified conferences than any other medical education provider in the United States. PER provides high-quality, evidence-based, CME-certified activities that translate the science of oncology into the art of patient care by featuring leading national and international faculty that focus on practice-changing advances that help the busy oncologist stay up-to-date with cutting-edge oncology knowledge and treatments. Accredited by the Accreditation Council for Continuing Medical Education, PER serves the broader oncology health care community, including physicians, nurses, nurse practitioners, physician assistants and pharmacists. PER is part of Michael J. Hennessy Associates Inc., a full-service health care communications company offering education, research and medical media.
# # #